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ABSTRACT
Systemic Sclerosis (SSc) is an autoimmune disorder of unknown etiology characterized
by severe and often progressive cutaneous and visceral fibrosis, pronounced alterations in the
microvasculature, and numerous cellular and humoral immune abnormalities. Clinically, SSc is
very heterogeneous encompassing a spectrum ranging from mild limited forms of skin sclerosis
with minimal internal organ involvement to severe skin and multiple internal organ fibrosis.
Mortality and morbidity in SSc are very high and are directly related to the extent of the fibrotic
and microvascular alterations. A better understanding of the pathogenesis of this incurable
disorder will help to better target and design effective therapy in the future.
Keywords: Systemic sclerosis, scleroderma, fibrosis, autoantibodies, transforming growth
factor , collagen genes, transcription factors.
•

Autoimmune disease of unknown etiology.

•

Severe and often progressive cutaneous and visceral organ fibrosis.

•

Numerous humoral and cellular immune abnormalities including production of specific
autoantibodies, cytokine and growth factor dysregulation and mononuclear cell infiltration of
affected tissues.

•

Transforming growth factor  and its regulatory pathways including the Smad proteins
appear to be intimately involved in SSc pathogenesis.

•

Abnormal regulation of expression of various collagen genes and of the transcriptional
factors involved.

•

Fibroproliferative vascular alterations and thrombosis responsible for the most serious
clinical events such as renal crisis and pulmonary hypertension.
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1.

Introduction.
Systemic Sclerosis (SSc) is an autoimmune inflammatory disorder of unknown etiology

characterized by severe and often progressive cutaneous and visceral fibrosis, pronounced
alterations in the microvasculature and frequent cellular and humoral immunity abnormalities as
patients with SSc almost universally harbor numerous autoantibodies, some which are diseasespecific. Clinically, SSc is heterogeneous ranging from mild limited skin sclerosis (sclerodactily
or acrosclerosis) with minimal organ involvement (limited SSc) to diffuse skin involvement and
severe fibrosis of multiple internal organs (diffuse SSc), and occasionally a fulminant course
with rapid development of vital organ failure and a lethal outcome (fulminant SSc). Morbidity
and mortality in SSc are very high and are related to the extent of the fibrotic and microvascular
alterations. A better understanding of the pathogenesis of this incurable disorder will help to
better target and design effective therapy in the future.
Although the exact mechanisms involved in the pathogenesis of SSc are not well
understood, there are three features responsible for the clinical and pathologic manifestations of
the disease: (1) excessive deposition of collagen and other connective tissue macromolecules in
skin and internal organs; (2) vascular lesions of small arteries; and (3) alterations of humoral and
cellular immunity.
At present, it is not clear which of the three components of SSc pathogenesis is of
primary importance or how they interrelate to cause the progressive fibrotic process. However,
there has been a remarkable progress in the understanding of numerous basic mechanisms, which
have shed light on the complex pathogenesis of the disease.
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2.

Are infectious agents involved in SSc pathogenesis?
The etiology of SSc is not known, however, it is currently accepted that the disease

results from complex interactions between one or more environmental factors and a genetic
predisposition in the host which eventually result in the development of severe, generalized, and
often progressive tissue fibrosis .
It has been postulated that infectious agents may be the causative agents of autoimmune
disorders including SSc and retroviruses and human cytomegalovirus (HCMV) among others,
have been considered putative etiologic agents. This hypothesis is based on observations
indicating that production of specific autoantibodies in SSc may be due to an antigen driven
response triggered by “molecular mimicry” between self-antigens sharing structural similarities
to a foreign protein of viral or bacterial origin. Thus, the autoantibodies may represent footprints
of the elusive etiologic agent. In support of this hypothesis it was shown that sequence
homologies exist between the p30gag retroviral proteins of various feline and murine viruses and
topoisomerase I, the marker SSc antigen recognized by anti-Scl-70 antibodies (1).
Furthermore, antibodies to certain retroviral proteins have been found in sera from
patients with SSc (2). Despite these observations a more direct evidence of retroviral
involvement in the etiology or pathogenesis of SSc is needed. Another putative etiologic agent
for SSc is HCMV. The possible involvement of HCMV is supported by the observations of
higher prevalence in patients with SSc of IgG anti-HCMV antibodies capable of binding the
HCMV late protein UL94 and inducing apoptosis in human endothelial cells (3), an increased
prevalence of IgA HCMV in patients positive for Scl-70 autoantibodies, the development of
severe fibro-proliferative vascular changes in certain cases of HCMV infections, and the
occurrence of autoantibodies recognizing the U1 snRNP primarily directed against a 70 kD
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protein in patients with HCMV infections (4). As is the case for retroviruses, there is no
evidence to conclusively link HCMV infections with the development of SSc or with its clinical
manifestations.
3.

Contribution of genetic factors.
The contribution of genetic factors to the development and expression of SSc is strongly

supported by: (1) the observation of familial clustering of the disease; (2) the high frequency of
occurrence of other autoimmune disorders and autoantibody positivity in SSc family members;
(3) differences in SSc prevalence and clinical manifestations among different ethnic groups; and
(4) the increased prevalence of certain human leukocyte antigen (HLA) and major
histocompatibility complex (MHC) alleles among different ethnic groups and among patients
with different types of disease or different patterns of autoantibodies (5). Although the
concordance of SSc among identical twins is only 5.9%, suggesting that the heritability
component is rather low for SSc, this frequency is still about 300 times higher than that expected
by chance alone. Furthermore, only a small group of twins has been studied (34 pairs) rendering
it difficult to draw definitive conclusions. Other evidence for the contribution of genetic factors
to the development of SSc has been gathered from the study of the frequency of occurrence of
SSc in the Choctaw American Indians from Oklahoma in whom the prevalence of SSc is 469
cases/million population in contrast with that of the general prevalence of SSc in the United
States of 242 to 286 cases/million population (6). The remarkably higher prevalence of SSc in
the Choctaw appears to be associated with differences in MHC and HLA allele expression when
comparing different ethnic groups. In the Choctaws, the HLA haplotypes found to be related
with disease expression are DRB1*1602, DQA1*0501, DQB1*0301, whereas, in Caucasian
populations from the United States and from Europe they are DRB1*1101, DRB1*1104,
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DQA1*1501, DQB1*0301, DRB1*0301, DQA1*0501, DQB1*0201. Certain patterns of disease
expression also appear to be different among ethnic groups. For example, African American
patients with SSc are more likely to be positive for anti-topoisomerase-1 antibodies, have worse
disease manifestations with more pronounced systemic involvement and a higher frequency of
pulmonary fibrosis. On the contrary, anti-centromere antibodies are more commonly seen in
Caucasian patients who display more limited disease with less systemic manifestations (5,6).
In addition to providing a receptive environment for the development of SSc, genetic
influences may also be involved in the phenotypic expression of the disease, thus, explaining the
remarkable variability and the wide expression of clinical manifestations. In the case of SSc,
these studies have been particularly focused on the potential influence of various genetic
polymorphisms on the severity and progression of the fibrotic process by promoting increased
collagen gene expression. In one study it was found that the presence of certain dinucleotide
repeats in the upstream region of COL1A2 in patients with SSc resulted in its increased
expression (7). Another study has shown that two different single nucleotide polymorphisms in
the gene for transforming growth factor  (TGF1), the potent profibrotic cytokine secreted from
activated T-lymphocytes, are present in higher frequency in patients with SSc than in normal
individuals (8). Also, a study of Japanese and Choctaw Indians with SSc found that a single
nucleotide polymorphism in the non-coding region of the fibrillin-1 gene at chromosome 15q
was strongly related to the development of SSc in these patients (9).
Although collectively these studies suggest an important contribution of genetic factors in
the pathogenesis of SSc and, in particular, in the expression of specific SSc clinical subsets, at
present, it appears more likely that genetic factors may provide a permissive environment that
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allows either the initiation of the disease process or its progression and development of clinical
manifestations.
4.

Microchimerism: Does it play a role in SSc pathogenesis?
A novel hypothesis suggesting that allogenic fetal and maternal cells which cross the

placenta during pregnancy may be involved in the pathogenesis of SSc has recently been
proposed. Fetal or maternal cells persist in the maternal or offspring blood and tissues likely as a
result of HLA II (DRB1) compatibility between the mother and the fetus (10). It has been
postulated that these engrafted fetal cells become activated by an environmental trigger and
subsequently mount a graft-versus-host reaction towards the mother or offspring, which may
result in the clinical symptoms of SSc. The identification of Y-chromosome sequences in the
DNA obtained from skin biopsy specimens from female SSc patients who had previously given
birth to male offspring provides strong support for this hypothesis (11). Also, the recent
demonstration of microchimerism of maternal origin in blood and tissues of the offspring might
explain the occurrence of SSc in nulliparous women and in men. There is substantial
controversy regarding this hypothesis since several recent studies have shown that fetal Y
chromosome DNA is present in normal controls, although other studies have indicated that it
may be the quantity and not the mere presence of fetal cells that may be the crucial contributory
factor in the pathogenesis of SSc (12,13). Thus the intriguing and provocative hypothesis of
microchimerism in the pathogenesis of SSc still remains controversial.
5.

Humoral immune system alterations.
The presence of specific autoantibodies is one of the most common manifestations of

SSc and greater than 90% of SSc patients have antinuclear antibodies in their serum. Numerous
autoantibodies have been described in SSc patients (Table 1). Some of these are extremely
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specific for SSc, whereas others are associated with different clinical manifestations of the
disease.
Anti-Scl-70 antibodies were initially described to recognize a 70-kD nuclear protein (14).
Subsequently, it was shown that these antibodies react with a 110-kD protein which has been
identified as DNA topoisomerase I (15). These antibodies are almost exclusively present in sera
from patients with the diffuse form of SSc. About 30-40% of patients with diffuse SSc harbor
these autoantibodies with a higher prevalence seen in African American patients.
Anti-centromere antibodies recognize several protein components of the tri-laminar
kinetochore. The most common anticentromere antibodies recognize three different antigens: a
17 kD (CENP-A), an 80 kD (CENP-B) and a 140 kD (CENP-C) centromere protein. These
antibodies are usually present in patients with the limited form of SSc and are seen in 80 to 96%
of these patients. In contrast to anti-Scl-70 antibodies, anti-centromere antibodies are only found
in about 10% of patients with diffuse SSc. These two autoantibodies are mutually exclusive, coexisting in the same patient only in rare instances.
Other autoantibodies less commonly seen in SSc patients are anti-RNA polymerases I
and III antibodies in patients with rapidly progressive disease and severe internal organ
involvement, anti-fibrillarin antibodies directed against a 34 kD nucleolar protein and commonly
found in diffuse SSc, and anti-PM-Scl antibodies directed against eleven different nucleolar and
nuclear proteins ranging in size from 20 kD to 11 kD which are usually related to a polymyositis
SSc overlap syndrome. Although autoantibodies in SSc are very common, it is generally
accepted that they are not directly involved in the clinical manifestations of the disease and their
titers do not correlate with disease activity or clinical severity.
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6.

Cellular immune system and cytokine alterations.
The presence of mononuclear cell infiltrates in affected skin and visceral organs from

SSc patients has long been recognized. Early in the presentation of SSc, biopsies from affected
skin show prominent macrophage and T-cell lymphocytic infiltrates (16). The cells in these
early infiltrates are CD14+ and express Class II MHC, suggesting that they are activated. Prior
activation of peripheral blood T cells in patients with SSc is also evident by the increased
expression of high affinity IL-2R on the T-cell membranes and the observation that sera from
SSc patients contain a three-fold higher level of serum IL-2. Subsequently, the majority of
tissue-bound T-cell lymphocytes is CD4+ (helper T-cells) expressing the activation marker Class
II MHC antigen DR. While this is true in most cases, a few studies have shown an increased
prevalence of CD8+ cells in lymphocytic infiltrates from the skin and lungs. Most of these cells
express / receptors rather than / receptors although / receptor bearing T-cells appear to be
predominant in bronchial alveolar lavage fluids of patients with SSc interstitial lung disease (17).
Further expansion of T-cells within the affected tissues appears to be oligoclonal as shown
recently in studies of T-cell receptor transcripts in SSc skin (18). The expanded T-cell
populations in affected SSc tissues are believed to release cytokines, which initiate and/or
perpetuate the fibrotic process as well as the endothelial and vascular alterations. Indeed, clones
of T-cells established from infiltrating lymphocytes isolated from affected SSc skin produce
cytokines capable of modulating fibroblast proliferation and collagen production, as well as,
various endothelial cell functions (19).
There are numerous cytokines which have been shown in in vitro studies to exert potent
effects on the production and/or degradation of collagens (20). However, it is very likely that the
ultimate effects of these cytokines on fibroblast biosynthetic activities depend on their
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concentration in the pericellular environment and on their relative proportions among a mixture
of a large number of other cytokines which often have opposing effects on the target cells.
7.

The TGF signaling pathway: A key component of pathologic tissue fibrosis.
Since the discovery of the potent profibrotic and immunomodulatory activities of TGF,

this growth factor has been considered one of the most likely molecules involved in the
pathogenesis of SSc (21) and other fibroproliferative diseases (22), and a plethora of publications
have described studies focused on this subject. Three functionally and structurally similar
isoforms of TGF exist in humans and they play important roles in embryonic development,
immune responses, and regulation of tissue repair following injury (23). One of the most
important effects of TGF is the stimulation of ECM synthesis evidenced by a remarkable
increase in the production of numerous matrix molecules. TGF also decreases the synthesis of
collagen-degrading metalloproteinases and stimulates the production of protease inhibitors such
as tissue inhibitors of metalloproteinases-1 (TIMP-1).
Small amounts of TGF appear to sensitize fibroblasts and maintain them in a
persistently activated state involving an autocrine mechanism which causes further production of
TGF. Activated monocytes from SSc patients secrete TGF and the upregulation of this
cytokine/growth factor appears to play a crucial role in the development of fibrosis in patients
with SSc. It also appears that SSc fibroblasts express increased numbers of TGF receptors
which might account for the increased TGF-induced signaling and the resulting increased
collagen production in these cells. TGF is synthesized as a 390-412 amino acid pre-pro-TGF
molecule which then undergoes glycosylation to form a pro-TGF monomer. This monomer is
then cleaved by endopeptidases to yield a 12.5 kDa monomer while the cleaved fragment
dimerizes to form a 75kDa latency binding peptide which assists in the folding of a 25 kDa
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dimer resulting from the dimerization of the 12.5 kDa monomers. A 135 kDa latency binding
peptide bearing mannose-rich carbohydrate then attaches to the 75 kDa latency binding peptide
to form the latent TGF complex (LTC) which is secreted by the cell. Outside the cell LTC
binds to mannose-6-phosphate receptors on cell membranes or to the extracellular matrix where
activated cells such as macrophages release serine proteases which cleave the LTC and release
active TGF (23). The intricate mechanisms involved in the transduction of TGF effects from
the cell surface to the responsive genes have been recently elucidated (24,25). BioactiveTGF
binds to the cell surface TGF II receptor (TRII) in target cells to form a receptor complex
which becomes activated and trans-phosphorylates, the TRI receptor causing its activation.
Signaling from the phosphorylated TGFI receptor to the nucleus then occurs through the Smad
family of proteins. Smad2 and Smad3 bind to the activated TGF receptor complex and they
also become phosphorylated. Phosphorylation allows these proteins to form a complex with
Smad4 which is a cytoplasmic protein involved in the translocation of the complex into the
nucleus. Smad7 is an inhibitory Smad which can bind to the TGF receptor complex and
prevent Smad2 or Smad3 phosphorylation. Once in the nucleus, Smad2/Smad4 or
Smad3/Smad4 complexes bind directly to specific DNA binding sites in the promoter regions of
target genes and activate their expression. The Smad3 complex binds to DNA sites in the
promoter region of responsive genes with the help of intranuclear proteins which act as
transcriptional partners. In contrast, Smad2 complexes do not bind to DNA promoter sites but
exert their effect through other transcription factors or co-activator proteins. A diagrammatic
representation of the TGF/SMAD pathway is shown in Figure 1. The potential involvement of
the Smad proteins (26) and, in particular, of Smad7 in the pathogenesis of SSc has been
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suggested by a recent study which described substantially reduced levels of Smad7 in SSc
fibroblasts and skin (27).
CTGF is another growth factor that appears also to play a crucial role in tissue fibrosis
(28). In addition to a potent profibrotic effect, CTGF also participates in angiogenesis, axial
development of the musculoskeletal system, structural organization of connective tissue, and
embryo implantation. TGF stimulates CTGF synthesis in fibroblasts, vascular smooth muscle
cells and endothelial cells. The CTGF produced by these cells in response to TGF stimulation
in turn stimulates the synthesis of such ECM components as type I collagen and fibronectin in
dermal and lung fibroblasts and very likely in endothelial cells. CTGF also appears to have an
autocrine function stimulating its own production and, thus, maintaining a continuous or
prolonged cycle of excessive scarring and fibrosis. Although the role of CTGF in the
pathogenesis of SSc has not been completely elucidated, it has been postulated that it may, under
certain conditions, represent a downstream mediator of TGF effects. Indeed, some studies have
shown that CTGF expression is markedly increased in affected SSc tissues including skin and
lung parenchyma.
Most recent studies on TGF regulation of fibroblast ECM production have focused on
Smad signaling, however, it has been postulated that non-Smad pathways may be involved in
TGF signaling. Certain intracellular enzymes have been identified to possibly play a role in
TGF signaling including protein kinase C- (PKC-), phosphatidylcholine-specific
phospholipase C (PLC), geranylgeranyl transferase I, stress-activated protein kinase p38, and
TGF-activated kinase (TAK). Selective or specific inhibition of enzymes involved in nonSmad pathways of TGFregulation resulted in down-regulation of collagen gene expression in
both normal and SSc fibroblasts. GGTI-298, a geranylgeranyl transferase I inhibitor caused a
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potent inhibition of both type I and III collagen expression in these cells (29), rottlerin, a potent
and highly-specific inhibitor of PKC-, also inhibited both type I and III collagen gene
expression in both normal and SSc fibroblasts. Furthermore, cultured SSc fibroblasts displayed
elevated levels of PKC-, providing support to the hypothesis that PKC- plays a role in the
pathogenesis of increased collagen gene expression in SSc (30). However, the precise role of
non-Smad pathways in the pathogenesis of tissue fibrosis in SSc has not been completely
elucidated.
8.

Alterations in the transcription of collagen genes.
A crucial element in the pathogenesis of SSc is the abnormal regulation of expression of

the genes involved in the production and deposition of type I collagen, the most prevalent protein
in fibrotic lesions from patients with SSc and the protein responsible for the most serious clinical
manifestations of the disease. Numerous studies have shown that SSc fibroblasts display an
increased expression of these genes which is determined at the transcriptional level. The
upregulated transcriptional activity of collagen genes in SSc appears to be autonomous and is
maintained even when cells are cultured in vitro for numerous passages. It is this persistent and
autonomous upregulation of expression of collagen genes which distinguishes the process of
normal wound healing from the disease state in SSc. The most important elements responsible
for the regulation of expression of the genes encoding type I collagen are located in the 5’
promoter and first intron regions. There are numerous elements which exert enhancer or
repressor functions on the overall transcriptional activity of these genes and are capable of
regulating both the basal production of collagen as well as its production during pathologic
conditions. Transcription factors are capable of specific binding to specific regulatory DNA
sequences in the 5’ promoter and in the first intron of collagen genes causing activation or
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suppression of collagen gene expression. The transcription factors involved in the regulation of
collagen gene expression are quite numerous and additional ones continue being identified and
described (31). Some of the most important and well-studied are listed in Table II. The CCAAT
box, for example, is a regulatory region present in the promoter region of the genes encoding 1
and 2 chains of type I collagen (COL1A1 and COL1A2). Three different CCAAT binding
factor proteins (CBF-A,B,C) may bind to this region and activate type I collagen transcription.
Another regulatory site is the Nuclear Factor-1 binding site, located in the proximal promoter
region of COL1A1 and COL1A2. Nuclear Factor-1, an intranuclear regulatory protein, binds to
these regions and also causes the activation of collagen gene expression. Sp1 is another
intranuclear transcription factor which binds to a GC-rich region in the proximal promoter at
sites near those recognized by NF1 and is a potent stimulator of collagen gene expression.
Elevated Sp1 and CBF binding to specific sequences in type I collagen genes has been
demonstrated in SSc fibroblasts (32,33). These observations indicate the crucial role that these
two transcription factors play in the development of tissue fibrosis in SSc. Another important
transcription factor which has been recognized and characterized recently is C-Krox (34). This
protein appears to exert potent downregulation of collagen gene expression and, thus, may
represent a counterbalance to Sp1 and CBF. The role of C-Krox in SSc, however, has not been
determined. Alterations in either the transcription factors or their binding sites may directly
relate to the pathogenesis of SSc, creating a mosaic of pathogenic possibilities that can be
targeted with new therapies for SSc.
9.

Endothelial cells and vascular alterations.
Vascular dysfunction appears to be one of the earliest clinical manifestations of SSc and

it has been suggested to be a crucial initiating event in SSc pathogenesis (35). Small blood
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vessels in affected tissues from SSc patients show perivascular cellular infiltration with activated
T cells similar to that present in affected skin and internal organs. It has been postulated that
cytokines or growth factors such as TGF- secreted by these activated lymphocytes cause
activation and injury of small vessel endothelial cells inducing their expression of MHC class I
and II antigens and adhesion ligand ICAM-1. As described above, TGF causes an upregulation
of CTGF which in turn induces an increased production of ECM components as well as an
upregulation of PDGF. PDGF is a potent endothelial cell mitogen which causes increased
endothelial cell proliferation. It has also been shown that in SSc there is a downregulation of
vascular endothelial growth factor (VEGF) which results in decreased and impaired
neovascularization. Chemo-attraction of fibroblasts into the vessel wall and transdifferentiation
of resident vessel wall fibroblasts into myofibroblasts occurs as a result of the effects of the
locally-secreted cytokines, leading to increased collagen synthesis and deposition. Endothelial
injury causes the subendothelium to be exposed to circulating platelets which eventually adhere
to it and initiate fibrin deposition and intravascular thrombus formation. The vascular
fibroproliferative lesions and intravascular platelet thrombosis inevitably result in a state of local
hypoxia in affected tissues. Recent studies have demonstrated that local hypoxia can further
cause tissue fibrosis by activation of collagen and TGF genes.
Vasodilation also appears to be impaired in SSc patients. Vasodilation is usually
controlled by both endothelial and nonendothelial (neurological) mechanisms. Endothelial cells
regulate vascular tone by secreting vasoactive substances such as nitric oxide and calcitoninrelated peptide which are vasodilatory as well as endothelin-I which is a potent vasoconstrictor in
patients with SSc. It appears that in SSc there is a relative deficiency of vasodilator molecules
and a relative increase of vasoconstrictor ones which in turn causes further vascular hypoxia and
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endothelial injury resulting in the production and release of additional cytokines from the
activated inflammatory cells, thus maintaining the vicious cycle of endothelial injury and
fibrosis. Indeed, several studies have demonstrated increased levels of endothelin and of its
receptors in affected SSc microvasculature as well as in parenchyma of affected tissues (36).
The effects of vascular dysfunction in patients with SSc are most dramatic when they involve the
pulmonary and renal arterioles, causing endothelial injury with subsequent intravascular
thrombus formation as well as fibrous tissue deposition in the myointimal region of the vessels.
The constellation of these multiple vascular alterations leads to renal crisis and pulmonary
hypertension, respectively, which are the most prevalent causes of morbidity and mortality in
patients with SSc.
10.

Conclusion.
Although a unified hypothesis encompassing all the components of SSc pathogenesis is

sought, owing to the heterogeneity of the disease, the answer may lie not in a single pathway but
in a constellation of different pathogenic mechanisms. A causative agent such as a virus of
chemical substance may initiate tissue inflammation in a patient with a genetic predisposition for
SSc. On the other hand, the initial event may be the engraftment of microchimeric cells after
materno-fetal cell transfer with a subsequent graft-versus-host event. The pathogenesis of SSc as
described above may follow a different path in individual patients although each of these
pathways would lead to the same end results of altered humoral and cellular immunity, vascular
endothelial lesions and, most importantly, excessive collagen deposition in skin and internal
organs. Thus, a better understanding of the pathogenesis of SSc and the formulation of valid and
testable hypotheses will undoubtedly provide the foundations to render reachable the goal of
developing novel and effective therapeutic agents for this incurable disease.
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Table I. Principal autoantibodies in Systemic Sclerosis.
Autoantibody
anti-Scl-70
anti-centromere

anti-RNA polymerase I
anti-fibrillarin
anti-PM-Scl
anti-nRNP
anti-7-2-RNP
anti-NOR-90
anti-mitochondrial
Anti-Ku
Anti-Th/To

Target Antigen
DNA topoisomerase I
Kinetochore proteins
CENP A (17 kDa)
CENP B (80 kDa)
CENP C (140 kDa)
Complex of 210-14 kDA proteins
Nucleolar protein of 34 kDa
Component of U3-RNP
Complex of 110-20 kDA
Nucleolar and nuclear proteins
Nuclear ribonucleoprotein
Nucleolar protein of 40 kDa
Complexed with 7-2 and 8-2 RNAs
Protein of 90 kDa localized to the
nucleolar organizer region
M2 complex of 70 kDA and
47 kDa proteins
Nucleolar heterodimer of 70 kDa and
80 kDa polypeptide chains
RNAse MRP and RNAse
P ribonucleoprotein complexes

Clinical Association
Diffuse SSc
Limited SSc

Progressive SSc,
organ involvement
Diffuse SSc
Polymyositis/SSc overlap
Mixed connective
tissue disease
Limited SSc
Lung involvement
Limited SSc associated
with PBC
Polymyositis/SSc overlap

CENP=centromere protein;PM=polymyositis; RNP=ribonuclear protein; NOR=nucleolar
organizing region.
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Table II. Selected transcription factors involved in the regulation of type I collagen gene
expression.

Transcription
Factor
CBF
(CCAAT binding factor)
CBF-A
CBF-B
CBF-C
NF-1
(nuclear factor-1)
Sp-1
(Zinc finger family)

IF1/IF2

c-Krox
(Zinc finger family)
AP1

Promoter
Binding Site
-100 to –96 bp

Effect on Type I
Collagen Gene
Expression
Activation

COL1A2

-350 to –300 bp

Activation

COL1A2

-303 to –279 bp
-164 to –159 bp
-128 to –123 bp

Activation

COL1A1
COL1A1

-129 to –107 bp
-190 to –170 bp
-160 to –130 bp
-133 to –71 bp

COL1A2
COL1A1

-165 to –155 bp
-195 to –168 bp

COL1A1

+292 to +670 bp
(first intron)

Target Genes
COL1A1
COL1A2

JunD
c-Jun
c-fos

19

Inhibition

Inhibition
Inhibition
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LEGENDS

Figure 1:

Diagrammatic representation of the TGF-/Smad cascade of collagen gene
activation.

Key for Figure: SSc=systemic sclerosis;TGF-= transforming growth factor-; PDFG=platelet
derived growth factor; CTGF= connective tissue growth factor; P=phosphorylation; TRII=
transforming growth factor  receptor 2; TRI=transforming growth factor  receptor 1.
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